Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Prominent IL-12 Production and Tumor Reduction in Athymic Nude Mice after Toxoplasma gondii Lysate Antigen Treatment

  • Pyo, Kyoung-Ho (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center) ;
  • Jung, Bong-Kwang (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center) ;
  • Xin, Chun-Feng (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center) ;
  • Lee, You-Won (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center) ;
  • Chai, Jong-Yil (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center) ;
  • Shin, Eun-Hee (Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center)
  • Received : 2014.09.18
  • Accepted : 2014.10.13
  • Published : 2014.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Toxoplasma gondii is an intracellular protozoan parasite that causes a Th1 cellular immunity. Our previous study showed that T. gondii lysate antigen (TLA) treatment in S180 tumor-bearing mice resulted in tumor reduction by suppressing CD31 expression, a marker of angiogenesis. In the present study, to investigate tumor suppressive effect of TLA under the absence of T lymphocytes, athymic nude mice were compared with euthymic mice in the anti-tumorigenic effect triggered by TLA in CT26 tumors. According to the results, intratumorally injected TLA reduced tumor growth and TIMP-1 level, a metastatic marker, in both euthymic and athymic mice. TLA treatment led to a sharp increase in IL-12 expression in serum cytokine profiling of athymic mice, and increased MyD88 signals in macrophages derived from the bone marrow, implying the activation of innate immunity. The selective induction of IL-12 by TLA treatment had an anti-tumorigenic effect.

Keywords

References

  1. Lehmann T, Marcet PL, Graham DH, Dahl ER, Dubey JP. Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci USA 2006; 103: 11423-11428. https://doi.org/10.1073/pnas.0601438103
  2. Lim H, Lee SE, Jung BK, Kim MK, Lee MY, Nam HW, Shin JG, Yun CH, Cho HI, Shin EH, Chai JY. Serologic survey of toxoplasmosis in Seoul and Jeju-do, and a brief review of its seroprevalence in Korea. Korean J Parasitol 2012; 50: 287-293. https://doi.org/10.3347/kjp.2012.50.4.287
  3. Pyo KH, Jung BK, Chai JY, Shin EH. Suppressed CD31 expression in sarcoma-180 tumors after injection with Toxoplasma gondii lysate antigen in BALB/c mice. Korean J Parasitol 2010; 48: 171-174. https://doi.org/10.3347/kjp.2010.48.2.171
  4. Jung BK, Pyo KH, Shin KY, Hwang YS, Lim H, Lee SJ, Moon JH, Lee SH, Suh YH, Chai JY, Shin EH. Toxoplasma gondii infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer's disease. PLoS One 2012; 7: e33312. https://doi.org/10.1371/journal.pone.0033312
  5. Miyahara K, Yokoo N, Sakurai H, Igarashi I, Sakata Y, Yoshida Y, Saito A, Hirose T, Suzuki N. Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats. J Vet Med Sci 1992; 54: 221-228. https://doi.org/10.1292/jvms.54.221
  6. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee YH. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 2007; 22 (suppl): S38-S46. https://doi.org/10.3346/jkms.2007.22.S.S38
  7. Hibbs JB Jr, Lambert LH Jr, Remington JS. Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis 1971;124: 587-592. https://doi.org/10.1093/infdis/124.6.587
  8. Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N, Chen X. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One 2011; 6: e24407. https://doi.org/10.1371/journal.pone.0024407
  9. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46 (suppl): S52-S61. https://doi.org/10.1007/PL00014051
  10. Egilmez NK, Kilinc MO. Tumor-resident $CD8^+$ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz) 2010; 58: 399-405. https://doi.org/10.1007/s00005-010-0097-7
  11. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168. https://doi.org/10.1016/S1359-6101(01)00032-6
  12. Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc 2008; pdb. prot5080 (doi: 10.1101/pdb.prot5080).
  13. Sznol M, Lin SL, Bermudes D, Zheng LM, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 2000; 105: 1027-1030. https://doi.org/10.1172/JCI9818
  14. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502. https://doi.org/10.1099/0022-1317-83-3-491
  15. Silobrcic V, Fredrickson G, Sedlacek R, Suit HD, Wolberg G. Immune reaction of tumor-bearing mice to Propionibacterium acnes and the antitumor effect of the bacteria. Cancer Immunol Immunother 1982; 14: 10-12.
  16. Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 2008; 47: 580-590. https://doi.org/10.1080/02841860802022976
  17. Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J. Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol Res 2003; 27: 521-528. https://doi.org/10.1385/IR:27:2-3:521
  18. Li D, Yu H, Xu TF, Li JH, Sun YF, Zhang WQ. Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo. Cell Mol Immunol 2008; 5: 225-230. https://doi.org/10.1038/cmi.2008.28
  19. Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother 2010; 59: 453-463. https://doi.org/10.1007/s00262-009-0764-x
  20. Wortis HH. Immunological responses of 'nude' mice. Clin Exp Immunol 1971; 8: 305-317.
  21. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165: 2665-2670. https://doi.org/10.4049/jimmunol.165.5.2665
  22. Del Rio L, Butcher BA, Bennouna S, Hieny S, Sher A, Denkers EY. Toxoplasma gondii triggers myeloid differentiation factor 88-dependent IL-12 and chemokine ligand 2 (monocyte chemoattractant protein 1) responses using distinct parasite molecules and host receptors. J Immunol 2004; 172: 6954-6960. https://doi.org/10.4049/jimmunol.172.11.6954
  23. Whitworth JM, Alvarez RD. Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opin Biol Ther 2011; 11: 751-762. https://doi.org/10.1517/14712598.2011.566854
  24. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, Hieny S, Sutterwala FS, Flavell RA, Ghosh S, Sher A. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005; 308: 1626-1629. https://doi.org/10.1126/science.1109893
  25. Lauw FN, Caffrey DR, Golenbock DT. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol 2005; 26: 509-511. https://doi.org/10.1016/j.it.2005.08.006
  26. Aliberti J, Reise Sousa C, Schito M, Hieny S, Wells T, Huffnagle GB, Sher A. CCR5 provides a signal for microbial induced production of IL-12 by CD8 $alpha^+$ dendritic cells. Nat Immunol 2000; 1: 83-87.
  27. Aliberti J, Serhan C, Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002; 196: 1253-1262. https://doi.org/10.1084/jem.20021183

Cited by

  1. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice vol.7, pp.45, 2014, https://doi.org/10.18632/oncotarget.12316
  2. NaHCO 3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5112
  3. Puzzling and ambivalent roles of malarial infections in cancer development and progression vol.143, pp.14, 2014, https://doi.org/10.1017/s0031182016001591
  4. Microorganisms in the Treatment of Cancer: Advantages and Limitations vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/2397808
  5. Characteristics of Infection Immunity Regulated by Toxoplasma gondii to Maintain Chronic Infection in the Brain vol.9, pp.None, 2014, https://doi.org/10.3389/fimmu.2018.00158
  6. The Neurotropic Parasite Toxoplasma gondii Induces Sustained Neuroinflammation with Microvascular Dysfunction in Infected Mice vol.188, pp.11, 2014, https://doi.org/10.1016/j.ajpath.2018.07.007
  7. Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53‐dependent apoptosis and anticancer effect vol.23, pp.5, 2014, https://doi.org/10.1111/jcmm.14207
  8. Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells vol.21, pp.18, 2020, https://doi.org/10.3390/ijms21186642